Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial
Authors
Armstrong, A. J.Clarke, Noel W
Thiery-Vuillemin, A.
Oya, M.
Procopio, G.
De Menezes, J. J.
Girotto, G. C.
Ghatalia, P.
Din, F. N. O.
Spiegelhalder, P.
Mincik, I.
Van Alphen, R. J.
Lumen, N.
Hosius, C.
Zhou, D. S.
Barker, L.
Dujka, M. E.
Saad, F.
Affiliation
Duke University Medical Center, Durham, NCIssue Date
2022
Metadata
Show full item recordCitation
Armstrong AJ, Clarke NW, Thiery-Vuillemin A, Oya M, Procopio G, De Menezes JJ, et al. Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301470.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.5050Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5050Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.5050